APA

Kuiper J. L., Heideman D. A. M., Würdinger T., Grünberg K., Groen H. J. M. & Smit E. F. (20150730). Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. : Clinical lung cancer.

Chicago

Kuiper Justine L, Heideman Danielle A M, Würdinger Tom, Grünberg Katrien, Groen Harry J M and Smit Egbert F. 20150730. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. : Clinical lung cancer.

Harvard

Kuiper J. L., Heideman D. A. M., Würdinger T., Grünberg K., Groen H. J. M. and Smit E. F. (20150730). Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. : Clinical lung cancer.

MLA

Kuiper Justine L, Heideman Danielle A M, Würdinger Tom, Grünberg Katrien, Groen Harry J M and Smit Egbert F. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. : Clinical lung cancer. 20150730.